The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The endocannabinoid (eCB) system, a neurochemical signalling system consisting of CB-receptors and their endogenous ligands, has been found to be involved in food intake of sweet and palatable foods. Activation of the eCB system increases food intake and vice versa. The mechanism behind this effect is still unknown and the current study aims at clarifying why sweet food intake increases. It is hypothesized that sweet taste intensity increases and that sweet taste is experienced as more pleasant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake

NCT02310347

Appetite Regulation

ACTIVE_NOT_RECRUITING NA

Cannabidiol and Emotional Stimuli

NCT02902081

Drug Addiction

COMPLETED NA

Cannabioids as a New Intervention for Amphetamine Dependence

NCT02952196

Amphetamine Addiction

WITHDRAWN PHASE2

Activation of the Endocannabinoid System and Cognition

NCT05226351

Post Traumatic Stress Disorder

COMPLETED NA

The Effects of Cannabidiol and ∆-9-THC in Humans

NCT01180374

Healthy

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensory Science

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T-C-P

Order of administrations: tetrahydrocannabinol - cannabidiol - placebo

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

T-P-C

Order of administrations: tetrahydrocannabinol - placebo - cannabidiol

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

C - T - P

Order of administrations: cannabidiol - tetrahydrocannabinol - placebo

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

C - P - T

Order of administrations: cannabidiol - placebo - tetrahydrocannabinol

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

P - T - C

Order of administrations: placebo - tetrahydrocannabinol - cannabidiol

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

P - C - T

Order of administrations: placebo - cannabidiol - tetrahydrocannabinol

Group Type EXPERIMENTAL

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tetrahydrocannabinol

Intervention Type DRUG

cannabidiol

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

delta-9-tetrahydrocannabinol THC CBD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI: 18.5 - 25 kg/m2
* Incidental cannabis use for at least one year, at least four times per year, but less than once a week.
* Dutch-speaking
* Willing to comply with the study procedures
* Having given written informed consent

* Restraint eating (men: score \> 2.90)
* Lack of appetite
* Having difficulties with swallowing/eating
* Usage of an energy restricted diet during the last two months
* Weight loss or weight gain of 5kg or more during the last two months
* Stomach or bowel disease
* Diabetes, thyroid disease, other endocrine disorders
* Use of daily medication except paracetamol
* Having taste or smell disorders (self-report)
* Being allergic/intolerant for products under study
* Previously experienced an adverse reaction to cannabinoids (e.g. anxiety, paranoia, nausea)
* Having (had) a schizophrenia or other psychotic illness
* Having a family history of schizophrenia or other psychotic illness
* Working at the Division of Human Nutrition (WUR)
* Current participation in other research from the Division of Human Nutrition (WUR)

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes